BridgeBio Pharma's CEO is Neil Kumar, appointed in Apr 2015, has a tenure of 11.08 years. total yearly compensation is $14.94M, comprised of 7% salary and 93% bonuses, including company stock and options. directly owns 2.7% of the company’s shares, worth €305.88M. The average tenure of the management team and the board of directors is 5 years and 6.3 years respectively.
Key information
Neil Kumar
Chief executive officer
US$14.9m
Total compensation
CEO salary percentage
6.99%
CEO tenure
11.1yrs
CEO ownership
2.7%
Management average tenure
5yrs
Board average tenure
6.3yrs
Recent management updates
Recent updates
CEO Compensation Analysis
How has Neil Kumar's remuneration changed compared to BridgeBio Pharma's earnings?
Date
Total Compensation
Salary
Company Earnings
Dec 31 2025
US$15m
US$1m
-US$725m
Sep 30 2025
n/a
n/a
-US$797m
Jun 30 2025
n/a
n/a
-US$776m
Mar 31 2025
n/a
n/a
-US$668m
Dec 31 2024
US$16m
US$988k
-US$536m
Sep 30 2024
n/a
n/a
-US$439m
Jun 30 2024
n/a
n/a
-US$454m
Mar 31 2024
n/a
n/a
-US$538m
Dec 31 2023
US$12m
US$742k
-US$643m
Sep 30 2023
n/a
n/a
-US$613m
Jun 30 2023
n/a
n/a
-US$573m
Mar 31 2023
n/a
n/a
-US$425m
Dec 31 2022
US$7m
US$1m
-US$481m
Sep 30 2022
n/a
n/a
-US$491m
Jun 30 2022
n/a
n/a
-US$509m
Mar 31 2022
n/a
n/a
-US$596m
Dec 31 2021
US$26m
US$725k
-US$563m
Sep 30 2021
n/a
n/a
-US$535m
Jun 30 2021
n/a
n/a
-US$495m
Mar 31 2021
n/a
n/a
-US$520m
Dec 31 2020
US$10m
US$550k
-US$449m
Sep 30 2020
n/a
n/a
-US$402m
Jun 30 2020
n/a
n/a
-US$346m
Mar 31 2020
n/a
n/a
-US$291m
Dec 31 2019
US$26m
US$503k
-US$261m
Compensation vs Market: Neil's total compensation ($USD14.94M) is above average for companies of similar size in the German market ($USD5.71M).
Compensation vs Earnings: Neil's compensation has been consistent with company performance over the past year.
CEO
Neil Kumar (46 yo)
11.1yrs
Tenure
US$14,944,585
Compensation
Dr. Neil Kumar, Ph D., is Executive Chairman of BridgeBio Oncology Therapeutics, Inc. from April 20, 2026. He serves as an Independent Director at Maze Therapeutics, Inc. since March 27, 2026.He has been...
Leadership Team
Name
Position
Tenure
Compensation
Ownership
Neil Kumar
Co-Founder
11.1yrs
US$14.94m
2.7% € 305.9m
Thomas Trimarchi
CFO & President
1.8yrs
US$5.83m
0.20% € 23.1m
Charles Homcy
Co-Founder
no data
US$1.12m
0.47% € 53.2m
Frank McCormick
Co-Founder
no data
US$1.10m
0.39% € 44.3m
Maricel Apuli
Chief Accounting Officer
3.3yrs
no data
0.054% € 6.1m
Uma Sinha
Chief Scientific Officer
10.1yrs
US$2.75m
no data
Richard Scheller
Chairman of Research & Development
7.3yrs
US$2.01m
no data
Eli Wallace
Chief Scientific Officer of Oncology
6.4yrs
no data
no data
Eric David
Chief Executive Officer of Gene Therapy
no data
no data
no data
Matthew Outten
Chief Commercial Officer
5yrs
no data
no data
Adora Ndu
Chief Regulatory Affairs Officer
4.3yrs
no data
no data
Jonathan Fox
President & Chief Medical Officer of Cardiovascular and Renal Diseases
4.2yrs
no data
no data
5.0yrs
Average Tenure
55.5yo
Average Age
Experienced Management: 2CL's management team is seasoned and experienced (5 years average tenure).
Board Members
Name
Position
Tenure
Compensation
Ownership
Neil Kumar
Co-Founder
11.1yrs
US$14.94m
2.7% € 305.9m
Charles Homcy
Co-Founder
7.5yrs
US$1.12m
0.47% € 53.2m
Frank McCormick
Co-Founder
2.6yrs
US$1.10m
0.39% € 44.3m
Fred Hassan
Lead Independent Director
4.8yrs
US$599.95k
0.010% € 1.1m
Ronald Daniels
Independent Director
6.3yrs
US$599.95k
0.0054% € 609.0k
Eric Aguiar
Independent Director
7.2yrs
US$599.95k
0% € 0
Randal Scott
Independent Director
5.9yrs
US$599.95k
0.0046% € 526.2k
Ali Satvat
Independent Director
10.2yrs
US$599.95k
0.082% € 9.3m
James Momtazee
Director
10.2yrs
US$599.95k
0.046% € 5.2m
Jennifer Cook
Director
6.4yrs
US$599.95k
0.0037% € 418.5k
Wen-Chaun Lo
Independent Director
5.9yrs
US$649.95k
0.030% € 3.4m
Andrea Ellis
Independent Director
4.8yrs
US$599.95k
0.0062% € 702.0k
6.3yrs
Average Tenure
63.5yo
Average Age
Experienced Board: 2CL's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/02 13:21
End of Day Share Price
2026/04/30 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BridgeBio Pharma, Inc. is covered by 37 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.